CORC

在结果中检索

CORC

浏览/检索结果: 共6条，第1-6条 帮助

限定条件                    
已选(0)清除 条数/页：   排序方式：
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Increased and sustained HBsAg loss in HBeAg positive CHB patients switched from NUC to Peg-IFN alfa-2a: A randomised open label trial (NEW SWITCH study) 会议论文
作者:  Hu, Peng;  Dou, Xiaoguang;  Jiang, Jian-ning;  Jia, Shang;  Zhang, Wen Hong
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/06
A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a (40KD) for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study 会议论文
作者:  Hu, Peng;  Jia, Shang;  Zhang, Wen Hong;  Gong, Guozhong;  Li, Yongguo
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19
ON-TREATMENT QUANTIFICATION OF HBSAG IN DIFFICULT-TO-TREAT PATIENTS WITH LAMIVUDINE RESISTANCE CAN HELP IDENTIFY THOSE MOST LIKELY TO ACHIEVE SUSTAINED POST-TREATMENT RESPONSE TO PEGINTERFERON ALFA-2A RESCUE THERAPY 会议论文
作者:  Hou, Jinlin;  Sun, Jian;  Xie, Qing;  Li, Xiuhui;  Zhang, Jiming
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19
EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A VERSUS ADEFOVIR DIPIVOXIL (ADV) IN TREATING LAMIVUDINE RESISTANT HBEAG POSITIVE CHB: AN INTERIM ANALYSIS OF A PROSPECTIVE RANDOMIZED STUDY 会议论文
作者:  Hou, Jinlin;  Sun, Jian;  Xie, Qing;  Li, Xiuhui;  Zhong, Jiming
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/19

©版权所有 ©2017 CSpace - Powered by CSpace